US Stock MarketDetailed Quotes
INKT MiNK Therapeutics
- 0.720
- -0.004-0.54%
Close Nov 27 16:00 ET
- 0.727
- +0.007+0.94%
Post 20:01 ET
28.48MMarket Cap-1946P/E (TTM)
0.729High0.716Low13.48KVolume0.716Open0.724Pre Close9.75KTurnover0.13%Turnover RatioLossP/E (Static)39.55MShares1.90052wk High-1.62P/B7.31MFloat Cap0.57052wk Low--Dividend TTM10.16MShs Float22.155Historical High--Div YieldTTM1.73%Amplitude0.570Historical Low0.723Avg Price1Lot Size
About MiNK Therapeutics Company
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Company Profile
SymbolINKT
Company NameMiNK Therapeutics
Listing DateOct 15, 2021
Issue Price12.00
Founded2017
CEODr. Jennifer S. Buell, PhD
MarketNASDAQ
Employees31
Fiscal Year Ends12-31
Address149 5th Avenue,Suite 500
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10010
Phone1-212-994-8250
Company Executives
- Name
- Position
- Salary
- Dr. Jennifer S. Buell, PhD
- President, Chief Executive Officer and Director
- 2.81M
- Christine M. Klaskin
- Treasurer, Principal Financial Officer and Principal Accounting Officer
- 29.62K
- Dr. Garo H. Armen, PhD
- Chairman of the Board
- 344.32K
- Dr. Robert Kadlec
- Director
- --
- Barbara Ryan
- Independent Director
- 154.25K
- Peter Behner
- Independent Director
- 111.45K
- Brian J. Corvese
- Independent Director
- 154.75K
- Ulf Wiinberg
- Independent Director
- 106.95K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data